FDA approves Merck's rare PAH drug at center of $11.5B Acceleron deal
The FDA on Tuesday cleared Merck’s pulmonary arterial hypertension treatment, which could quickly become a blockbuster for the New Jersey pharma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
